Log in or Sign up for Free to view tailored content for your specialty!
Bipolar Disorder News
APA launches digital mental health registry
The American Psychiatric Association on Wednesday announced the launch of PsychPRO 2.0, a mental health registry that offers psychiatrists enhanced options to engage with patients, track outcomes and streamline data for quality reporting.
FDA approves sublingual treatment for agitation
BioXcel Therapeutics has announced the FDA approval of Igalmi, a sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Log in or Sign up for Free to view tailored content for your specialty!
Differences in neurodevelopmental maturation indicate higher risk for bipolar disorder
Differences in neurodevelopmental maturation of structural brain networks leave certain adolescents at high genetic risk for bipolar disorder, according to an Australian study published in the American Journal of Psychiatry.
Serious mental illness tied to elevated CV risk; uncontrolled risk factors prevalent
Individuals with serious mental illnesses such as bipolar disorder and schizophrenia may experience greater 10- and 30-year CV risk compared with those without a serious mental illness, researchers reported.
People with severe mental disorders have ‘persistent mortality gap’
Compared with the general population, individuals with mental disorders had increased risk for mortality across all disorders, according to results of a systematic review and meta-regression published in Journal of Psychiatric Research.
Collaborators to develop ketamine treatments for mental health, chronic pain
Revitalist Lifestyle and Wellness Ltd. has announced a partnership with PharmaTher Holdings Ltd. to develop treatment protocols with ketamine for individuals with mental health disorders and chronic pain.
Sublingual dexmedetomidine reduces agitation in patients with bipolar disorder
A sublingual film form of the selective alpha-2a-adrenergic receptor agonist dexmedetomidine significantly reduced mild to moderate agitation in patients with bipolar disorder, a phase 3 randomized trial showed.
Lybalvi for schizophrenia, bipolar disorder shows positive phase 3b results
Alkermes announced positive topline results from its phase 3b study of Lybalvi in young adults with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness.
Sunovion, Otsuka partner to study treatment for bipolar-linked major depressive episodes
Sunovion and Otsuka announced the first patient has been randomly assigned in their phase 3 clinical study of non-racemic amisulpride for treating major depressive episodes linked to bipolar I disorder.
Ketamine offers short-term benefits to patients with suicidal ideation, French study finds
Ketamine provided rapid benefits to hospitalized patients with suicidal ideation; however, more research is needed to determine its long-term impact, according to findings from a French study published in The BMJ.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read